32.04

1.42% -0.46

After Hours: 32.04

Progyny Inc (PGNY)

Overview News Price History Option Chain Discussions Forecast

Progyny Inc stock is currently priced at $32.04, with a 24-hour trading volume of 567.00K. It has seen a -1.42% decreased in the last 24 hours and a -13.50% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $32.41 pivot point. If it approaches the $31.84 support level, significant changes may occur.

Previous Close:

$32.50

Open:

$32.46

24h Volume:

567.00K

Market Cap:

$3.08B

Revenue:

$1.09B

Net Income/Loss:

$62.04M

P/E Ratio:

65.39

EPS:

0.49

Net Cash Flow:

$185.17M

1W Performance:

-2.02%

1M Performance:

-13.50%

6M Performance:

+6.62%

1Y Performance:

-1.63%

1D Range:

$31.99

$32.70

52W Range:

$29.44

$44.95

Progyny Inc Stock (PGNY) Company Profile

Name

Progyny Inc

Sector

Healthcare (1191)

Industry

Health Information Services (62)

Phone

212 888 3124

Address

1359 Broadway, New York, NY

Employee

167

Twitter

@Progyny

Next Earnings Date

2024-05-23

Latest SEC Filings

PGNY's Discussions on Twitter

Progyny Inc Stock (PGNY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-03-24	Initiated	Barclays	Overweight
Sep-27-23	Initiated	Canaccord Genuity	Buy
May-22-23	Initiated	BTIG Research	Buy
Apr-21-23	Initiated	Cantor Fitzgerald	Overweight
Jan-05-23	Downgrade	SVB Leerink	Outperform → Mkt Perform
Sep-16-22	Initiated	KeyBanc Capital Markets	Overweight
Sep-07-22	Initiated	Truist	Buy
Dec-02-21	Initiated	Jefferies	Buy
Nov-22-21	Downgrade	Citigroup	Buy → Neutral
Sep-30-21	Initiated	Berenberg	Buy
Aug-12-21	Initiated	Barclays	Overweight
Jun-02-21	Downgrade	Guggenheim	Buy → Neutral
Apr-29-21	Resumed	JP Morgan	Overweight
Mar-10-21	Upgrade	BofA Securities	Neutral → Buy
Jul-01-20	Initiated	SVB Leerink	Outperform
Jun-02-20	Initiated	Guggenheim	Buy
Nov-19-19	Initiated	Citigroup	Buy
Nov-19-19	Initiated	Goldman	Buy
Nov-19-19	Initiated	JP Morgan	Overweight
Nov-19-19	Initiated	Piper Jaffray	Overweight
Nov-19-19	Initiated	SVB Leerink	Outperform

View All

Progyny Inc Stock (PGNY) Latest News

Progyny, Inc. Announces Details for Its First Quarter 2024 Results Report

GlobeNewswire Inc.

Progyny and Fertility Matters Canada Recognize Canadian Fertility Awareness Week to Advocate for Expanded Access to Family Building Care

GlobeNewswire Inc.

Progyny Inc Stock (PGNY) Financials Data

Progyny Inc (PGNY) Revenue 2024

PGNY reported a revenue (TTM) of $1.09 billion for the quarter ending December 31, 2023, a +38.34% rise year-over-year.

Progyny Inc (PGNY) Net Income 2024

PGNY net income (TTM) was $62.04 million for the quarter ending December 31, 2023, a +104.35% increase year-over-year.

Progyny Inc (PGNY) Cash Flow 2024

PGNY recorded a free cash flow (TTM) of $185.17 million for the quarter ending December 31, 2023, a +140.00% increase year-over-year.

Progyny Inc (PGNY) Earnings per Share 2024

PGNY earnings per share (TTM) was $0.62 for the quarter ending December 31, 2023, a +106.67% growth year-over-year.

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption expenses for clients and their employees. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.